Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer (CCC-Cancer)

November 5, 2026 updated by: National Cancer Centre, Singapore

Evaluating the Effectiveness, Acceptability and Feasibility of a Communication and Care Coordinator (CCC) Model in Facilitating Serious Illness Communication (SIC) and Care in Patients With Cancer

The goal of this clinical trial is to evaluate the communication and care coordinator (CCC) model in a national cancer institute and assess the utility of the model in facilitating serious illness communication (SIC) and care for patients with cancer.

The study aims are:

  • To assess the effectiveness of the CCC model in improving patient outcomes.
  • To assess the effectiveness of the CCC model in increasing rates of SIC and advance care planning (ACP) record documentation.
  • To assess the acceptability of the CCC model to patients and clinicians.
  • To evaluate the feasibility of implementing a CCC model in oncology care.

Researchers will compare results from the CCC intervention arm and usual care arm, to see if the CCC model can help improve patient outcomes and facilitate SIC between patients and clinicians.

Patient participants will:

  • Follow the assignment of their clinician, who will be assigned randomly to either the usual care group or the intervention group.
  • Be assigned a CCC and receive 6 CCC sessions over the course of 3 months (if assigned to CCC intervention arm).
  • Complete 3 study assessment visits at baseline, Week 6, and 3 months
  • Be invited to a one-time interview to share their study experience (optional, if selected and if in CCC intervention arm).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Timely SIC may facilitate earlier preferred plan of care documentation and improve patients' sense of peacefulness, hopefulness, and connectedness with their clinicians. The primary goal of the study is to evaluate the CCC model in a national cancer institute and assess the utility of the model in facilitating SIC and care for patients with cancer through a stepped wedge cluster randomized trial. This approach delivers crucial, empirical insights into how SIC can be efficiently and effectively delivered and potentially allow larger scale implementation and dissemination of the CCC model in Singapore, as an effective model for delivering patient support and facilitating patient-clinician communication in patients with advanced cancer.

Study Type

Interventional

Enrollment (Estimated)

560

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Benton PT TAM, MSc

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patient Participants

  • Aged 21 and above
  • Diagnosed with (a) advanced cancer (stage 3 or 4) or (b) non-advanced cancer, but at high risk of recurrence
  • Able to speak English or Chinese, irrespective of race

Clinicians

  • Oncologists who are at least of designation of associate consultant and above in NCCS

Exclusion Criteria:

Patient Participants

  • Disoriented and thus not able to sign informed consent
  • Diagnosed with untreated hearing or visual loss or psychiatric illness
  • Active suicidal ideation

Clinicians

  • Overseas/not practising in Singapore for a significant amount of time

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CCC Intervention Arm

Each participant will be assigned a CCC and receive 6 CCC sessions over the course of 3 months.

CCC sessions will be on exploring participant's illness journey thus far, their concerns, values and priorities.

No Intervention: Usual Care Arm

Each participant will continue to be followed by the oncologist and receive usual care but will not receive CCC intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Communication Quality
Time Frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Feeling Heard and Understood Survey (FHU) is a validated 4-item scale that has been used in palliative care to measure effectiveness of the SIC conversations and the value of the therapeutic relationship between the care team and the patient. The lowest possible score is 0 and the highest possible score is 16, with a higher score indicating that the care team listens well, respects patient's needs, and provides clear communication.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Quality of Life per FACT-G7
Time Frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Cancer Therapy-General-7 Item version (FACT-G7) is a 7-item questionnaire designed to quickly and effectively capture the most relevant issues to cancer. FACT-G7 scores could potentially range from 0-28, with a higher score indicating a better quality of life.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Health Utility
Time Frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

EuroQOL Group 5-Dimension (EQ-5D-5L) contains a 5-item descriptive system measuring 5 dimensions: mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression; a visual analogue scale (VAS) measuring overall health status. EQ-5D Index Value (Utility Score) ranges from 0 to 1.0 with higher value indicating better health-related quality of life. The VAS ranges from 0 to 100, with higher scores reflecting better self-rated health.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Spiritual Well-Being
Time Frame: Baseline, Week 6 after Baseline, and 3 months Post Enrolment.

Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) is a validated 12-item survey that is commonly used in the palliative care setting. It has 3 subscales (meaning, peace and faith). Scores in each subscale can potentially range from 0-16 and the total scores can range from 0-48. A higher score indicates greater spiritual well-being, better ability to find purpose in life and drawing comfort from spiritual resources.

Baseline, Week 6 after Baseline, and 3 months Post Enrolment.
Healthcare Utilization - Rate of Unplanned Acute Hospital Utilization
Time Frame: From Study Enrolment to 3 months Post Enrolment.

The rate of unplanned acute hospital utilization through the emergency department during the study will be collected.

From Study Enrolment to 3 months Post Enrolment.
Healthcare utilization - Length of hospital stay
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of stay in hospital (bed days) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Hospital Bill
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on hospital bill size will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Type of oncological treatment
Time Frame: From 3 months prior to study enrolment until 3 months after study enrolment.

Data on the type of oncological treatment used will be collected.

From 3 months prior to study enrolment until 3 months after study enrolment.
Healthcare utilization - Chemotherapy usage (line)
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the line of chemotherapy (first, second or third or subsequent (fourth and onwards)) will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Intensive care unit visit
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of intensive care unit visit
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of intensive care unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - High dependency unit visit
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the number of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Length of high dependency unit visit
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the length of high dependency unit visits will be collected.

From Study Enrolment until Date of Death, up to 3 years.
Healthcare utilization - Location of death
Time Frame: From Study Enrolment until Date of Death, up to 3 years.

Data on the location of death will be collected.

From Study Enrolment until Date of Death, up to 3 years.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability - Satisfaction
Time Frame: 3 months Post Enrolment.

Client satisfaction survey is a 4-item, 4-point scale survey in which patients provide ratings on their satisfaction with the intervention, and their views on its relevance, timeliness, and impact. It has been validated in research studies in the outpatient setting around mental health support. Score can range from 4-16, with a higher score indicating greater client satisfaction.

3 months Post Enrolment.
Feasibility - Approach-to-Enrolment Rates
Time Frame: From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.

Approach-to-enrolment rates - where feasibility is defined that at least 60% of those patients approached could be enrolled into the study.

From Commencement of Study Recruitment till the End of Recruitment, up to 24 months.
Feasibility - Patient Retention Rate
Time Frame: Baseline through Study Completion, estimated as up to 3 years.

Patient retention rate - where feasibility is defined that at least 80% of enrolled patients will be able to participate in the study for the planned study duration (3 months).

Baseline through Study Completion, estimated as up to 3 years.
Effectiveness - SIC and ACP documentation
Time Frame: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

The number of SIC and ACP documentation per clinician per enrolled patient during the study duration will be tracked during the intervention period(s) and during the control period(s). Clinical notes will also be read to evaluate if there was relevant documentation by clinician on SIC related issues.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Effectiveness - Time spent
Time Frame: From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years

Time spent by CCC in this model and estimated time spent by clinicians on SICs will be collected.

From Commencement of Study Enrollment through Study Completion, estimated as up to 3 years
Acceptability - Clinician experience
Time Frame: At end of intervention period (28th month).

Clinicians will be surveyed using a modified version of the Clinician Experience Survey (CES). The original CES was developed by Ariadne Labs for the purposes of assessing clinicians perceived feasibility and barriers in engaging patients in SIC. The researchers will modify the CES to form a 4-item scale (score range 4-16), with a higher score indicating greater clinicians' satisfaction with the CCC intervention.

At end of intervention period (28th month).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Shirlyn NEO Hui Shan, MD, PhD, National Cancer Centre, Singapore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

July 21, 2026

First Submitted That Met QC Criteria

July 24, 2026

First Posted (Actual)

July 29, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe